In the last week, the market has stayed flat, but it's up 20% over the past year with earnings forecast to grow by 19% annually. As investors navigate these conditions, identifying stocks with strong fundamentals becomes crucial for capturing potential growth. Penny stocks, though a somewhat outdated term, still highlight smaller or less-established companies that can offer significant value; we've identified three such stocks that combine sound balance sheets with promising potential.

We'll examine a selection from our screener results.

Zentalis Pharmaceuticals (ZNTL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for cancer treatment in the United States, with a market cap of $287.59 million.

Operations: Zentalis Pharmaceuticals, Inc. currently does not report any revenue segments.

Market Cap: $287.59M

Zentalis Pharmaceuticals, Inc., with a market cap of US$287.59 million, is a pre-revenue biopharmaceutical company focused on cancer therapeutics. Recently added to multiple Russell indexes, it reflects increased visibility in the investment community. The company is advancing its lead candidate, azenosertib, through late-stage trials for ovarian cancer and has secured Fast Track Designation from the FDA. Despite being unprofitable and having high share price volatility, Zentalis maintains a strong balance sheet with no debt and sufficient cash runway for over a year. Recent leadership appointments aim to bolster its commercial strategy as it prepares for potential product launches.

Cytek Biosciences (CTKB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cytek Biosciences, Inc. is a cell analysis solutions company offering tools for biomedical research and clinical applications, with a market cap of approximately $561.77 million.

Operations: The company generates revenue from its Scientific & Technical Instruments segment, totaling $204.17 million.

Market Cap: $561.77M

Cytek Biosciences, Inc., with a market cap of US$561.77 million, is currently unprofitable but generates revenue from its Scientific & Technical Instruments segment totaling US$204.17 million. The company has a strong balance sheet with short-term assets exceeding both short and long-term liabilities, and more cash than total debt. Recent developments include the introduction of the Cytek Borealis system at CYTO 2026, showcasing advanced capabilities in flow cytometry that enhance research flexibility and scalability. However, recent index exclusions may impact investor sentiment despite having an experienced management team and board of directors.

Duluth Holdings (DLTH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Duluth Holdings Inc. is a U.S.-based retailer specializing in casual wear, workwear, outdoor apparel, and accessories for men and women, with a market cap of approximately $175.76 million.

Operations: The company generates revenue primarily from its online retail segment, which accounts for $561.07 million.

Market Cap: $175.76M

Duluth Holdings, with a market cap of US$175.76 million, remains unprofitable as losses have grown 68.1% annually over five years. Despite this, the company maintains a solid balance sheet; short-term assets of US$163.1 million cover both short and long-term liabilities comfortably. Debt management is prudent, with a reduced debt-to-equity ratio and operating cash flow covering debt by 223%. Recent earnings show improved net loss figures from last year but highlight continued challenges in revenue growth and asset impairments. The experienced board and management team aim for strategic resets to stabilize financial performance amidst volatility concerns.

Turning Ideas Into Actions

• Click here to access our complete index of 331 US Penny Stocks.
• Curious About Other Options? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.